Blueprint Medicines Corp is a leading pharmaceutical company based in the United States, specializing in developing innovative drug treatments for diseases related to abnormal kinase activation. With a medium risk ESG score of 22.3, the company's focus on sustainability and governance is evident in its small molecule drug pipeline for cancer and rare genetic diseases. Notable drug candidates include AYVAKIT for systemic mastocytosis and BLU-808 for mast cell disorders. Additionally, Blueprint Medicines has promising treatments like BLU-956 and BLU-222 for breast cancer in its pipeline.